107 related articles for article (PubMed ID: 15897591)
1. A neutralizing anti-fibroblast growth factor 8 monoclonal antibody shows potent antitumor activity against androgen-dependent mouse mammary tumors in vivo.
Shimada N; Ishii T; Imada T; Takaba K; Sasaki Y; Maruyama-Takahashi K; Maekawa-Tokuda Y; Kusaka H; Akinaga S; Tanaka A; Shitara K
Clin Cancer Res; 2005 May; 11(10):3897-904. PubMed ID: 15897591
[TBL] [Abstract][Full Text] [Related]
2. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions.
Maruyama-Takahashi K; Shimada N; Imada T; Maekawa-Tokuda Y; Ishii T; Ouchi J; Kusaka H; Miyaji H; Akinaga S; Tanaka A; Shitara K
Prostate; 2008 May; 68(6):640-50. PubMed ID: 18213631
[TBL] [Abstract][Full Text] [Related]
3. High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8.
Tanaka A; Furuya A; Yamasaki M; Hanai N; Kuriki K; Kamiakito T; Kobayashi Y; Yoshida H; Koike M; Fukayama M
Cancer Res; 1998 May; 58(10):2053-6. PubMed ID: 9605740
[TBL] [Abstract][Full Text] [Related]
4. Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells.
Ruohola JK; Viitanen TP; Valve EM; Seppänen JA; Loponen NT; Keskitalo JJ; Lakkakorpi PT; Härkönen PL
Cancer Res; 2001 May; 61(10):4229-37. PubMed ID: 11358849
[TBL] [Abstract][Full Text] [Related]
5. Androgen and fibroblast growth factor 8 (FGF8) downregulation of thrombospondin 1 (TSP1) in mouse breast cancer cells.
Mattila MM; Tarkkonen KM; Seppänen JA; Ruohola JK; Valve EM; Härkönen PL
Mol Cell Endocrinol; 2006 Jul; 253(1-2):36-43. PubMed ID: 16723184
[TBL] [Abstract][Full Text] [Related]
6. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
7. The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells.
Song Z; Powell WC; Kasahara N; van Bokhoven A; Miller GJ; Roy-Burman P
Cancer Res; 2000 Dec; 60(23):6730-6. PubMed ID: 11118059
[TBL] [Abstract][Full Text] [Related]
8. FGF-8b increases angiogenic capacity and tumor growth of androgen-regulated S115 breast cancer cells.
Mattila MM; Ruohola JK; Valve EM; Tasanen MJ; Seppänen JA; Härkönen PL
Oncogene; 2001 May; 20(22):2791-804. PubMed ID: 11420691
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix.
Inamoto T; Yamochi T; Ohnuma K; Iwata S; Kina S; Inamoto S; Tachibana M; Katsuoka Y; Dang NH; Morimoto C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3470-7. PubMed ID: 16740772
[TBL] [Abstract][Full Text] [Related]
10. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
[TBL] [Abstract][Full Text] [Related]
11. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
[TBL] [Abstract][Full Text] [Related]
12. Proliferation of Shionogi carcinoma 115 cells by glucocorticoid-induced autocrine heparin-binding growth factor(s) in serum-free medium.
Yamanishi H; Nonomura N; Tanaka A; Nishizawa Y; Terada N; Matsumoto K; Sato B
Cancer Res; 1991 Jun; 51(11):3006-10. PubMed ID: 2032238
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
14. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
[TBL] [Abstract][Full Text] [Related]
15. Syndecan-1 regulates FGF8b responses in S115 mammary carcinoma cells.
Viklund L; Vorontsova N; Henttinen T; Salmivirta M
Growth Factors; 2006 Jun; 24(2):151-7. PubMed ID: 16801134
[TBL] [Abstract][Full Text] [Related]
16. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.
Wallner L; Dai J; Escara-Wilke J; Zhang J; Yao Z; Lu Y; Trikha M; Nemeth JA; Zaki MH; Keller ET
Cancer Res; 2006 Mar; 66(6):3087-95. PubMed ID: 16540658
[TBL] [Abstract][Full Text] [Related]
18. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.
Kim KJ; Wang L; Su YC; Gillespie GY; Salhotra A; Lal B; Laterra J
Clin Cancer Res; 2006 Feb; 12(4):1292-8. PubMed ID: 16489086
[TBL] [Abstract][Full Text] [Related]
19. A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells.
Miyamoto S; Iwamoto R; Furuya A; Takahashi K; Sasaki Y; Ando H; Yotsumoto F; Yoneda T; Hamaoka M; Yagi H; Murakami T; Hori S; Shitara K; Mekada E
Clin Cancer Res; 2011 Nov; 17(21):6733-41. PubMed ID: 21918176
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effect of antibody against basic fibroblast growth factor on androgen- or glucocorticoid-induced growth of Shionogi carcinoma 115 cells in serum-free culture.
Lu J; Nishizawa Y; Tanaka A; Nonomura N; Yamanishi H; Uchida N; Sato B; Matsumoto K
Cancer Res; 1989 Sep; 49(18):4963-7. PubMed ID: 2766270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
